【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Overview of the AMD and Other Retinal Diseases Market, 2014-2025
2.1 Market to Make Rapid Strides to 2025
2.2 Lucentis Still Holds Over 60% of the Total Market
2.2.1 Novartis the Leading Presence in the Market
2.3 Which are the Most Significant Disease Areas for the Market?
2.3.1 Nearly 200 Million People with AMD?
2.3.2 Over 100 Million with DR
2.3.3 First RVO Estimates Suggest Patient Population of 16 Million
2.3.4 Wet AMD Still the Main Source of Revenues in the Market
2.4 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
2.5 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
2.6 DR: Coming Into Clinical Focus, with DME the Main Target
2.7 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
2.8 Projections for All Segments, 2014-2025
3. Approved Products in the AMD and Other Retinal Diseases Market, 2014-2025
3.1 Will the Current Products Dominate the Market Through 2025?
3.2 Lucentis: The Market Leader, But For How Long?
3.2.1 Shadow of Avastin Still Hangs Over Lucentis
3.2.2 CATT Study Results: Clinical Differences Still Have Yet to Emerge
3.2.3 Eylea: The Bigger Threat to Lucentis?
3.2.4 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
3.2.5 Improving Cost and Compliance for Lucentis
3.2.6 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
3.2.7 Lucentis Revenue Forecast 2014-2025
3.3 Eylea: Pretender to the Throne?
3.3.1 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
3.3.2 First Wave of Eylea’s Expansion Finally Beginning to Break?
3.3.3 Into DME and Other New Indications
3.3.4 Zaltrap Targeting Solid Tumour Markets
3.3.5 How Far Can Eylea’s Momentum Carry It?
3.3.6 Eylea Revenue Forecast 2014-2025
3.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
3.4.1 Judicial Review Averted in the UK by Price Adjustment
3.4.2 Multiple Attempts to Block Off-Label Avastin Since 2007
3.4.3 Roche and Novartis Challenge CATT’s Headline Conclusions
3.4.4 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
3.4.5 Will Anything Dislodge Avastin from its Central Position?
3.4.6 Avastin Revenue Forecast, 2014-2025
3.5 Visudyne (Valeant/Novartis): Declining Sales Throughout the Forecast Period
3.5.1 Visudyne Revenue Forecast, 2014-2025
3.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
3.6.1 Jetrea Revenue Forecast, 2014-2025
4. Wet AMD Segment, 2014-2025
4.1 Eylea: The Segment’s Biggest Short-Term Driver
4.2 Pipeline for wAMD: The Leading Candidates
4.3 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
4.3.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
4.3.2 Ophthotech Goes Public to Fund Phase 3 Effort
4.3.3 Ophthotech Partners with Novartis for Fovista
4.3.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
4.3.5 The Move toward Combination Therapies
4.4 Other Growth Factor Targets in the Pipeline
4.4.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
4.4.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
4.4.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
4.4.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
4.5 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
4.5.1 A Chinese Competitor: Where Will Conbercept Fit In?
4.5.2 Binding Affinity Comparable to Eylea
4.6 Do We Need New Anti-VEGFR Agents or Delivery Systems?
4.6.1 AGN-150998 DARPin (Allergan): Novel Protein With Extended Half-Life
4.6.2 ESBA 1008 (Alcon): Single-Chain Monoclonal Antibody Fragment
4.6.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
4.6.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
4.6.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
4.6.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
4.7 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
4.7.1 Verisome System and IBI-30089 (Icon Bioscience)
4.7.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
4.8 Other Targets Under Investigation in wAMD Drug Development
4.8.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
4.8.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
4.8.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
4.8.4 First Ophthalmic Complement Factor Inhibitor, AL-78898A (Alcon), Misses Primary Endpoint
4.8.5 Factor C5: A More Promising Target Addressed by ARC1905 Aptamer (Ophthotech) and LFG316 (Novartis)
4.8.6 Integrins: Another Blockable Component of the Neovascularisation Cascade?
4.8.7 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
4.8.8 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
4.8.9 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003
4.8.10 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
4.8.11 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
4.9 Regenerative Medicine Approaches
4.9.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
4.9.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
4.9.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
5. Dry AMD Segment, 2014-2025
5.1 Dry AMD Segment to Emerge in the Forecast Period
5.2 Who Will Achieve the Big Breakthrough in Dry AMD?
5.3 MC-1101 (MacuCLEAR): Leading the Pack?
5.3.1 Increasing Choroidal Blood Flow with Repurposed Product
5.3.2 Novel Endpoints in Phase 3 Study
5.3.3 Can MacuCLEAR Make It?
5.4 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
5.4.1 Data Expected in July 2016
5.4.2 Other Visual Cycle Modulators
5.5 High Hopes for Complement Inhibition in Dry AMD
5.5.1 Lampalizumab (Roche): The Big News of ARVO 2013
5.5.1.1 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
5.5.2 AL-78898A (Alcon): Phase 2 Trial in Dry AMD Terminated
5.5.3 Soliris (Alexion): Out of the Running?
5.6 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
5.6.1 Medidur Fluocinolone Acetonide (Alimera Sciences): Insert in Phase 2
5.6.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
5.7 Neuroprotection: One of Modern Medicine’s Holy Grails
5.7.1 Tandospirone (Alcon): No News on Serotonin 1A Agonist
5.7.2 NT-501 (Neurotech): Some Promising Data in Dry AMD Studies
5.7.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
5.7.4 RN6G (Pfizer): Amyloid Beta-Binding Monoclonal Antibody Still in Studies
5.7.5 VAR10200 (Varinel): A Preclinical Candidate to Watch
5.8 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
5.8.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
5.8.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
5.8.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
5.8.4 Biotime: Stem Cell leader with Dry AMD Interests
5.8.5 First iPSC Trial in Japan in Dry AMD Patients
5.8.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
5.9 Other Treatments for Dry AMD
6. Diabetic Retinopathy Segment, 2014-2025
6.1 Segment to Grow in Importance as Diabetes Epidemic Continues
6.2 DR Options Grow with DME Addressed by New Agents
6.3 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
6.4 Lucentis: The Game Changer for DR?
6.5 New Anti-VEGF Additions
6.5.1 Is Eylea Better than Lucentis and Avastin for DME?
6.6 Steroids in Development for DR
6.6.1 Iluvien (Alimera/pSivida): New Option in European Markets
6.6.2 A New Hope? Optina (Ampio Pharmaceuticals)
6.6.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
6.6.4 SK-0503 (Sanwa Kagaku Kenkyusho): Potential DME and BRVO Treatment
6.6.5 Cortiject (Santen): Prodrug Candidate
6.6.6 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
6.7 Other Products in Development for DR
6.7.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
6.7.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
6.7.3 TriLipix (Abbott): No New Development for Promising Drug
6.7.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
6.7.5 Darapladib (GlaxoSmithKline): Possible New Use for Atherosclerosis Drug
6.7.6 Jetrea (ThromboGenics/Novartis): Possibilities in DME?
7. Regional Market Breakdown, 2014-2025
7.1 Which Markets Hold the Most Revenue Growth Potential?
7.2 The US: Leading Market for Retinal Diseases
7.3 Japan: Strong Market Potential
7.4 EU5: Ageing Populations to Drive Market Growth
7.5 BRIC Nations: The Biggest Growth Driver for the Market
8. Qualitative Industry and Market Analysis, 2015-2025
8.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
8.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
8.3 Opportunities: New Markets and R&D Synergies
8.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
8.5 Social: Low Diagnosis, Low Compliance
8.6 Technological: Innovation for the Eye
8.7 Economic: Off-Label Treatment and Reimbursement Issues
8.8 Political: The Demography and Diabetes Challenges
9. Research Interviews
9.1 Interview with Philip G. Ralston, Jr., MacuCLEAR (Part 1)
9.1.1 MC-1101: Identifying and Treating Chiou Syndrome
9.1.2 Preventing Dry AMD Progression
9.1.3 Treating the Root Cause of Dry AMD
9.1.4 Phase 3: Endpoints and Prospects for MC-1101
9.2 Interview with Philip G. Ralston, Jr., MacuCLEAR (Part 2)
9.2.1 MC-1101: Progress in Clinical Trials
9.2.2 MC-1101 More Effective in Early to Mid-Range AMD
9.2.3 Partnerships and Expected Launch of MC-1101
10. Report Conclusions
10.1 The Age of Lucentis: Nearing Its Conclusion?
10.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
10.3 Indications Outside Wet AMD to Gain in Importance
10.4 Dry AMD Market Has Huge Potential
10.5 Fovista Most Prominent Among the Pipeline Candidates
10.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
【レポート販売概要】
■ タイトル：加齢黄斑変性（AMD）及びその他の網膜疾患治療薬の世界市場：滲出型（ウェット型）、萎縮型（ドライ型）、糖尿病性網膜症■ 英文：Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025
■ 発行日：2015年2月
■ 調査会社：visiongain
■ 商品コード：VGAIN503045
■ 調査対象地域：グローバル
- ラックピニオン式ステアリング装置の世界市場2019-2023About this market In electric power steering (EPS), only the rack and pinion type steering system are used. Therefore, with the adoption of EPS increasing in automobiles, the demand for automotive rack and pinion steering system is also going up. EPS serves as an input for many safety systems, including lane keep assist and electronic stability control. Technological advances have helped steering …
- 医療機器業界のM&A及び投資動向（四半期別）：Q3 2013Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q3 2013 Summary GlobalData’s “Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q3 2013” report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the power industry. The report provides detailed information on M&As, equity/debt offerings, private eq …
- 世界のスマートガラス市場動向及び予測2014 – 2020Smart glass is also known by switchable glass, dimmable glass or dynamic glass. It is a kind of glass which changes its light transmission properties according to the provided stimulus. Based on whether, they require an electrical stimulus to respond or the level of control it offers to users; it can be categorized into Active or Passive. Electrochromic, SPD, and Liquid crystal are some of the act …
- 軍用機向けヘッドアップディスプレイ（HUD）の世界市場About HUD An HUD is a display indicator that displays the key flight information onto a transparent screen positioned in front of a pilot's line of sight. HUD finds its applications in the automotive and aviation sectors. It helps increase the situational awareness and enhances safety margins in these sectors. The following are the primary components of an HUD: combiner, projector unit, display pa …
- アミンの世界市場予測2016-2026Amines – our new study reveals industry trends, R&D developments and predicted revenues Visiongain assesses that the global amines market will reach $14.43bn in 2016. This definitive new report identifies where the business opportunities are. Amines are versatile chemicals which are used across a wide range of industries and applications including agrochemicals, personal care, cleaning products, p …
- Sorin S.p.A.：市場シェア分析Sorin S.p.A. Market Share Analysis Summary GlobalData’s new report, “Sorin S.p.A. Market Share Analysis” provides in-depth information on Sorin S.p.A.’s market position in the different medical equipment markets it operates in. The report provides Sorin S.p.A. market share information in four key market categories – Cardiac Rhythm Management, Cardiovascular Prosthetic Devices, Cardiovascular Surge …
- クラッディングの世界市場分析：クラッディング、鋼、アルミ、複合材パネル、繊維セメント、テラコッタ、セラミックThe global cladding market is expected to reach USD 111.1 billion by 2025, according to a new report by Grand View Research, Inc. Growing demand for enhanced moisture management & energy efficiency in project exteriors, especially from key construction industry participants including architects & designers. The shift in trend towards protecting exterior walls and growing construction of nonresiden …
- 世界のCAM（Computer-aided Manufacturing）市場動向（2012-2016）Introduction to the Market Computer-aided manufacturing (CAM) software solution provides efficient methods for manufacturing critical 2D and 3D objects with ease and better quality. It enables the calculation of tool paths based on the geometric dimension of the model, generates G code and M code, and controls feed rate, tooling, and other spindle-related operations. This software solution assists …
- エアロスタットシステムの世界市場：気球、飛行船、ハイブリッドThe global aerostat systems market has been estimated to be worth USD 5.42 Billion in 2016 and is expected to be valued at USD 10.95 Billion by 2021, registering a CAGR of 15.10% during the forecast period. On the basis of product type, the aerostat systems market has been segmented into balloon, airships and hybrid. The segment comprising airships is projected to be the fast-growing segment in th …
- 世界のモバイルセキュリティー市場動向（2012-2016）TechNavio's analysts forecast the Global Mobile Security market to grow at a CAGR of 47.21 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing popularity of smartphones and tablets. The Global Mobile Security market has also been witnessing an increased adoption of bring your own device policy. However, the increasing complexity of mobile dev …
- 世界の企業ネットワークセキュリティー市場動向（2012-2016）TechNavio's analysts forecast the Global Enterprise Network Security market to grow at a CAGR of 6.6 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing virtualization of servers. The Global Enterprise Network Security market has also been witnessing an increasing adoption of network security solutions by small and medium business. However, t …
- 融着接続機の世界市場予測（～2022年）The fusion splicer market was valued at USD 570.5 Million in 2016 and is expected to reach USD 762.3 Million by 2022, at a CAGR of 4.72% during the forecast period. Moreover, the fusion splicer market registered a shipment of 65,735 units in 2016 and is expected to reach 97,353 units by 2022, at a CAGR of 6.52% during the forecast period. Many countries are focusing on innovations and expansions i …
- 世界の小売産業ITセキュリティ市場：Global Retail Security Market 2014-2018TechNavio's analysts forecast the Global Retail Security market to grow at a CAGR of 28.12 percent over the period 2014-2018. One of the key factors contributing to this market growth is the increasing focus to reduce retail shrinkage. The Global Retail Security market has also been witnessing the increasing focus on reducing the man power by the retailers. However, the high cost of ownership of r …
- 複合機（MFP）の世界市場2016-2020MFPs can perform multiple functions like printing, faxing, scanning, and photocopying. These are used mainly in homes and offices due to their small size, versatility, reliability, and ease of use. For businesses, MFPs help to reduce capital costs and provide flexibility, as they have multiple functions. This eliminates the need for purchasing different peripherals such as copiers, printers, and s …
- 粘着テープの世界市場2016-2020About Adhesive Tapes Adhesive tapes stick to substances when pressure is applied, without the need for solvent, heat, or any other activator. Adhesives are coated on these tapes, either on one side or both sides. Many variants like single-sided, double-sided, adhesive transfer or transfer adhesive, single-coated, double-coated, carton sealing, masking, electrical and electronics are available in t …
